Capstone Holding highlighted accelerating demand for stone in global construction markets. This industry trend is directly supportive of Capstone’s strategy, as the company builds scale in stone distribution through Carolina Stone and its recently announced, on-track LOI. Recent industry research projects a 4.1% CAGR for natural stone over the next five years, driven by rising adoption among developers and homeowners. Capstone has built a leading stone platform through HHT’s Stone Business, Heller’s Stone, Carolina Stone, and a recently signed LOI, positioning the company to capitalize on this demand tailwind. Capstone operates across 32 states with a strong network of proprietary brands, positioning it to meet growing demand with consistent supply and quality. With stone demand rising and a remodeling rebound expected, Capstone reaffirms its $100 million 2026 run-rate revenue target and highlights continued gross-margin expansion. “We’re seeing a renaissance in demand for stone products, and given their durability, sustainability, and aesthetic advantages, we expect this momentum to continue,” said Matthew Lipman, CEO of Capstone Holding Corp. “Through a series of strategic acquisitions, we’ve built one of the most sophisticated and scaled stone distributors in the United States, and we believe we are exceptionally well-positioned to capture this market tailwind.”
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAPS:
- Capstone Holding reaffirms $100M 2026 run-rate revenue target
- Capstone Completes Acquisition of Carolina Stone Holdings
- Capstone debuts hardscape, landscape products at Hardscape North America
- Capstone Holding announces $3.25M draw to advance acquisition
- Capstone Therapeutics Issues Second Convertible Note
